Metoclopramide Mercury Pharmaceuticals (Ireland) (Metoclopramide Hydrochloride)

The drug blocks dopamine D2 receptors in the brain’s chemoreceptor trigger zone and in the gastrointestinal tract. This reduces the emetic signal, increases acetylcholine activity, promotes coordinated stomach contractions, speeds gastric emptying, and strengthens the lower esophageal sphincter.

The specific dose and duration are determined by the prescribing clinician based on the patient’s condition, age, renal function and response to therapy. Healthcare professionals follow local guidelines and product labeling to set an appropriate regimen.

Safety data are limited, and Metoclopramide should only be used during pregnancy or lactation if the potential benefit outweighs any risk. Clinicians should evaluate each case individually and consider alternative therapies when possible.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Metoclopramide differs from many antiemetics by acting as a dopamine antagonist and a gastro‑prokinetic. Unlike serotonin antagonists such as ondansetron, it also accelerates gastric emptying, making it useful for conditions like gastroparesis. However, it carries a higher risk of extrapyramidal side effects.

Metoclopramide injectable solution should be stored at ambient temperature, preferably below 25 °C. Keep the vial in its original packaging, protect it from light and moisture, and discard any product that appears discolored or contains particles.

The medication is supplied as a sterile injectable solution for intramuscular or intravenous injection. Administration technique, rate and site are determined by the prescriber, who follows standard aseptic procedures and monitors the patient for any immediate reactions.

Serious adverse events include acute dystonia, neuroleptic malignant syndrome, tardive dyskinesia with prolonged use, severe depression or suicidal thoughts, and anaphylaxis. Patients should be educated to report any unexplained muscle rigidity, fever, confusion or mood changes promptly.

Metoclopramide is contraindicated in individuals with known hypersensitivity to the drug, those with a history of seizure disorders, severe depression, or Parkinson’s disease, and in patients receiving MAO inhibitors within the past 14 days. Caution is also advised for patients with renal or hepatic impairment.